NCT01189643

Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

A Pilot Trial of Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

• Status: Active Not Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 1 Year – 29 Years
• Healthy volunteers: Not accepted

Summary

This study adds irinotecan, temozolomide and bevacizumab to the chemotherapy regimen currently used to treat Desmoplastic small round cell tumor (DSRCT). The investigators are doing this study to find out what effects, good and/or bad, the combination of irinotecan, temozolomide and bevacizumab has on the patient and the DSRCT cancer.

Conditions

• Sarcoma
• Desmoplastic Small Round Cell Tumor (DSRCT)

Interventions

Type	Name	Description
DRUG	irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator	Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab- will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.

Timeline

• Start date: 2010-08-01
• Primary completion: 2026-08-01
• Completion: 2026-08-01
• First posted: 2010-08-26
• Last updated: 2025-09-05

Locations

1 site across 1 country: United States